Bionano Genomics (BNGO) Operating Leases (2021 - 2026)

Bionano Genomics has disclosed Operating Leases across 6 years of filings, most recently posting $2.5 million for Q1 2026.

• Operating Leases for Q1 2026 came in at $2.5 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $2.5 million (changed N/A YoY), and the FY2025 annual result was $2.5 million, up 1616.55% from the prior year.
• Operating Leases came in at $2.5 million for Q1 2026 at Bionano Genomics, up from $2.5 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $5.5 million in Q4 2022 to a low of $145000.0 in Q4 2024.
• The 5-year median for Operating Leases is $3.9 million (2023), against an average of $3.7 million.
• Across the five-year window, Operating Leases sank 95.96% in 2024 and surged 1616.55% in 2025, its largest moves.
• Bionano Genomics' Operating Leases stood at $5.5 million in 2022, then tumbled by 34.77% to $3.6 million in 2023, then tumbled by 95.96% to $145000.0 in 2024, then soared by 1616.55% to $2.5 million in 2025, then advanced by 0.72% to $2.5 million in 2026.
• The last three Operating Leases figures came in at $2.5 million (Q1 2026), $2.5 million (Q4 2025), and $2.6 million (Q3 2025), per Business Quant data.